Android app on Google Play

Cytokinetics (CYTK) Regains Nasdaq Listing Compliance

January 25, 2013 4:04 PM EST Send to a Friend
On January 24, 2013, Cytokinetics, Incorporated (Nasdaq: CYTK) received a notice from The Nasdaq Stock Market ("Nasdaq") confirming that for the last 10 consecutive business days, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1).

As previously reported, the Company received notice from Nasdaq on June 18, 2012 that the Company’s common stock had failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. On December 18, 2012, the Company transferred its listing to the Nasdaq Capital Market and Nasdaq provided the Company until June 17, 2013 to achieve compliance with the Listing Rule 5450(a)(1) requirement.

Nasdaq has informed the Company that this matter is now closed.




You May Also Be Interested In


Related Categories

Corporate News

Add Your Comment